Precision BioSciences Inc (DTIL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$7.47+1.36%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · DTIL
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(20.9) + peer(0.2*-3.3) + term(0.0) → 6.64% (capped ±15.0)
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On August 6, 2026, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results and provided a business update for the quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated by referen…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On May 5, 2026, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated by reference into, this Item 2.02 (includin…
Results of Operations and Financial Condition. On March 12, 2026, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated by reference into, this Item…
and this Item 7.01 (including the Press Release attached hereto as Exhibit 99.1) of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any registration statement or other filing of the Company under the Securities Act of 1933, as amended, or the Ex…
Results of Operations and Financial Condition. Although it has not finalized its full financial results for the year ended December 31, 2025, Precision BioSciences, Inc. (the “Company”) expects to report that it had approximately $137 million in cash, cash equivalents, and restricted cash as of December 31, 2025. This estimate is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2025, or its re…
Results of Operations and Financial Condition. On November 3, 2025, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Results of Operations and Financial Condition. On August 7, 2025, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Results of Operations and Financial Condition. On May 15, 2025, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Results of Operations and Financial Condition. On March 26, 2025, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Results of Operations and Financial Condition. Although it has not finalized its full financial results for the year ended December 31, 2024, Precision BioSciences, Inc. (the “Company”) expects to report that it had approximately $108.5 million in cash, cash equivalents, and restricted cash as of December 31, 2024 before the receipt of $2.5 million from TG Therapeutics and other cash inflows in January 2025. This estimate is unaudited and preliminary and does not present all information neces…
Results of Operations and Financial Condition. On November 4, 2024, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Results of Operations and Financial Condition. Although it has not finalized its full financial results for the quarter ended September 30, 2024, Precision BioSciences, Inc. (the “Company”) expects to report that it had approximately $121 million in cash, cash equivalents, and restricted cash as of September 30, 2024. This estimate is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of September 30, 2024, and…
Results of Operations and Financial Condition. On August 1, 2024, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Results of Operations and Financial Condition. On May 13, 2024, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
of this Current Report on Form 8-K is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. Registration statements or other documents filed with the SEC shall not incorporate this information by reference, except as otherwise expressly stated in such filing. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 199…
Results of Operations and Financial Condition. On March 27, 2024, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.